Notable Results | Stage | Safety | Scalability | |
---|---|---|---|---|
ART during acute infection | Long-term post-therapy viral load control in a minority of individuals [16, 17, 23–30]. | Clinical/pre-clinical | High | Low (few patients are detected HIV+ at acute infection) |
Viral reactivation with HDACI’s | Possible disruption of latency [48, 49, 53–55]. No viral reservoir reduction [49]. | Clinical/pre-clinical | Medium | High |
Viral reactivation with cytokines | IL-7 might disrupt latency but replenishes the viral reservoir [57–59]. | Clinical | Medium | Medium/high |
Gene therapy for disruption of CCR5 | Mixed impact on viral load (depending on the genetic background) [66]. Possible immunologic improvement [67]. | Clinical | Medium (long-term effects unknown) | Very low |
Allogeneic stem cell transplant | Likely sterilizing cures in the second “Berlin Patient” [60, 61, 63] and in the “Boston Patients” [68, 69]. | Clinical | Very low | Very low |
Addition of auranofin and BSO to ART | Long-term post-therapy control in chronically SIVmac251 infected macaques [74, 81]. | Late pre-clinical | Medium/high (good safety profile for individual drugs in humans) | High |
Therapeutic vaccine with whole virus-pulsed dendritic cells | Post-therapy viral load control in a subset of macaques [88]. Viral load and viral load set-point reduction in a subset of ART-naïve [89, 90] and ART-treated patients [91], respectively | Clinical | High | Medium |
Administration of broadly neutralizing antibody/ies | Long-term post-therapy control in chronically SHIV(env) infected macaques starting from low viral loads [95] | Late pre-clinical | High | High |